[{"orgOrder":0,"company":"NeuroTherapia","sponsor":"CRU Early Phase Unit Kistarcsa","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NTRX-07","moa":"Cannabinoid receptor 2 (CB2)","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroTherapia \/ CRU Early Phase Unit Kistarcsa","highestDevelopmentStatusID":"8","companyTruncated":"NeuroTherapia \/ CRU Early Phase Unit Kistarcsa"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"NTRX-07","moa":"Cannabinoid receptor 2 (CB2)","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroTherapia \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"8","companyTruncated":"NeuroTherapia \/ Alzheimer\u2019s Association"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"NTRX-07","moa":"Cannabinoid receptor 2 (CB2)","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroTherapia","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"NeuroTherapia \/ Cleveland Clinic","highestDevelopmentStatusID":"8","companyTruncated":"NeuroTherapia \/ Cleveland Clinic"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NTRX-07","moa":"Cannabinoid receptor 2 (CB2)","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroTherapia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroTherapia \/ Undisclosed"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Brain Trust Accelerator Fund Ii","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series A Financing","leadProduct":"NTRX-07","moa":"Cannabinoid receptor 2 (CB2)","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"NeuroTherapia \/ Brain Trust Accelerator Fund Ii","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTherapia \/ Brain Trust Accelerator Fund Ii"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Cruint Global Consulting Pte Ltd | Firalis SA | Pharma-Regist Kft.","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NTRX-07","moa":"Cannabinoid receptor 2 (CB2)","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroTherapia \/ Cruint Global Consulting Pte Ltd | Firalis SA | Pharma-Regist Kft.","highestDevelopmentStatusID":"8","companyTruncated":"NeuroTherapia \/ Cruint Global Consulting Pte Ltd | Firalis SA | Pharma-Regist Kft."},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Integrium | Orange County Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"NTRX-07-SDD","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroTherapia \/ Integrium | Orange County Research Center","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTherapia \/ Integrium | Orange County Research Center"}]